<DOC>
	<DOCNO>NCT00151853</DOCNO>
	<brief_summary>The purpose study study efficacy PPSB-SD VP-VI patient , receive anticoagulant treatment undergo acute cardiac surgery cardiopulmonary bypass ( CPB ) .</brief_summary>
	<brief_title>Study Use PPSB-SD VP-VI Patients With Anticoagulant Therapy Undergoing Acute CPB Surgery</brief_title>
	<detailed_description>The value oral anticoagulant coumarin derivative therapy prophylaxis thrombosis universally acknowledge . These medicinal product use prevention cerebral infarction , patient atrial fibrillation secondary prevention myocardial infarction . In case elect surgery , effect coumarin derivative reverse termination coumarin treatment administration vitamin K orally , i.m . i.v. , restore production vitamin K dependent coagulation factor . For patient due undergo acute surgery , unfavourable await endogenous production vitamin K dependent coagulation factor production.After CPB surgery , patient need control coagulated state . Two product suitable rapidly increase concentration vitamin K dependent coagulation factor , fresh frozen plasma ( FFP ) prothrombin complex concentrate ( PCC ) . These product contain factor II , VII , IX X help restore normal level clot fraction.Administration product prior CPB surgery decrease INR level acceptable surgery . In Academic Hospital Leuven standard procedure case acute elect CPB surgery administration VP-VI , FFP-product make OCTAPHARMA . In study standard treatment 2x 400 ml VP-VI compare treatment PPSB Solvent Detergent® ( PPSB-SD ) accord prescription regimen CAF-DCF . PPSB-SD PCC product make Sanquin Plasma Products ( Netherlands ) CAF-DCF ( Belgium ) . The regimen prescribe CAF-DCF enables calculate quantity PPSB-SD administer basis patient ’ weight , initial INR target INR . The expected outcome study patient receive PPSB-SD target INR reach frequently rapidly compare patient receive VP-VI .</detailed_description>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>age least 18 year due undergo ( semi ) acute cardiac surgery relatively stable haemodynamic condition . body weight less 100 kg inform consent patient well control acenocoumarol , phenprocoumon warfarin . patient overdose acenocoumarol , phenprocoumon warfarin ( INR &gt; 7.8 ) due undergo ( semi ) acute cardiac surgery hepatic insufficiency renal insufficiency anaphylactic reaction administration blood product past disseminated intravascular coagulation ( DIC ) active thrombosis/pulmonary embolism intracardial thrombus patient treat platelet inhibitor , except aspirin ( acetylsalicylic acid ) , treat aprotinine pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>CPB</keyword>
	<keyword>oral anticoagulant therapy</keyword>
	<keyword>plasma</keyword>
	<keyword>PCC</keyword>
</DOC>